Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSPPT 2-TT: amlodipine-folic acid tablet versus amlodipine for primary prevention of first ischemic stroke in hypertensive patients with MTHFR C677T TT genotype
CTR20222387Phase 4Active
- Sponsor
- Shenzhen Ausa Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amlodipine, folic acid in essential hypertension, sponsored by Shenzhen Ausa Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
amlodipinefolic acid
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20222387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222387.